Evaluation of the Clinical and Biological Consequences of Levothyrox® Formula Modification

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-11

Study Completion Date

2019-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the recent excipient modification of Levothyrox® in France for a bioequivalent formula has clinical and biological consequence for the patients. The investigators also plan to describe the patient journey in terms of levothyroxine based drugs since this formula modification of Levothyrox®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

NCT01916304

Hypothyroidism

COMPLETED PHASE2

Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding

NCT04878614

Hypothyroidism

TERMINATED PHASE4

Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism

NCT04288115

Subclinical Hypothyroidism

COMPLETED PHASE4

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

NCT05823012

Hypothyroidism

COMPLETED PHASE2

REduction of LEvothyroxine in Adults; a SElf Controlled Study

NCT05821881

Hypothyroidism

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Levothyrox® is a levothyroxine based drug marketed in France in order to substitute a lack of thyroid hormones. Because of a lack of stability during time and because of wide inter-batch variability in terms of active molecule, the National Agency of Safety of Medicaments (ANSM) ask to the market authorization holder to develop a new formula without lactose. This new formula, which has been proven to be bioequivalent has been marketed since march 2017 in France. Some patients were predicted to have their thyroid function imbalance because of this modification. The purpose of the study is to analyse, on the patients treated by Levothyroxine® in how many patients this modification has clinical and biological consequences.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

self completed questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Thyroid disorder treated by Levothyroxine
* Age over 18 year old
* TSH plasma level within the 12 months before formulation modification
* TSH plasma level within the 6 months after formulation modification

Exclusion Criteria

\- Thyroid dysfunction (hypo or hyperthyroidism) despite Levothyroxine treatment, ie TSH plasma level out of normal range within the 6 months before formula modification

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No